Jeito Capital Co-Leads $76 Million Series A Financing For Cdr-Life, Its 10Th Investment Since Its Launch

Apr 13, 2022•over 3 years ago

Amount Raised

$76 Million

Round Type

series a

Paris

Description

Jeito Capital ("Jeito"), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a $76 million Series A financing round in CDR-Life, a privately-held biotech company developing a new generation of immuno-oncology therapies.

Company Information

Company

Cdr Life

Location

Paris, Ile De France, France

About

CDR-Life is a privately held, biotherapeutics company leveraging its unique antibody technology, M-gager®, to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC). CDR-Life is advancing a robust pipeline of novel fully cancer-directed T-cell engagers in various solid tumors. The team behind CDR-Life has extensive experience in all key areas of biologics development, hold numerous patents, and has previously invented new marketed medicines. CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide. For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Jeito Capital Co-Leads $76 Million Series A Financing For Cdr-Life, Its 10Th Investment Since Its Launch

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information